Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies

Nieves Carbonell, Gerardo Aguilar, Rafael Ferriols, Rotzel Huerta, José Ferreres, Marisa Calabuig, Mar Juan, Carlos Ezquer, Javier Colomina, M. Luisa Blasco
Nieves Carbonell
aMedical Intensive Care Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain
bINCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nieves Carbonell
Gerardo Aguilar
bINCLIVA Health Research Institute, Valencia, Spain
cAnesthesiology and Critical Care Departament, Hospital Clínico Universitario de Valencia, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Ferriols
bINCLIVA Health Research Institute, Valencia, Spain
dDepartment of Pharmacy, Hospital Clínico Universitario de Valencia, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rotzel Huerta
aMedical Intensive Care Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain
bINCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Ferreres
aMedical Intensive Care Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain
bINCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marisa Calabuig
bINCLIVA Health Research Institute, Valencia, Spain
eDepartment of Hematology, Hospital Clínico Universitario de Valencia, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mar Juan
aMedical Intensive Care Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain
bINCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Ezquer
bINCLIVA Health Research Institute, Valencia, Spain
dDepartment of Pharmacy, Hospital Clínico Universitario de Valencia, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Colomina
bINCLIVA Health Research Institute, Valencia, Spain
fDepartment of Microbiology, Hospital Clínico Universitario de Valencia, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Luisa Blasco
aMedical Intensive Care Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain
bINCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01782-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

Ceftolozane-tazobactam (C/T), a novel fifth-generation cephalosporin/β-lactamase inhibitor combination active against multidrug-resistant (MDR) Pseudomonas aeruginosa, is currently approved by the U.S. Food and Drug Administration (FDA) to treat complicated intra-abdominal and urinary tract infections at the label dosage (1 g/0.5 g/8 h intravenously), as well as nosocomial and ventilator-associated pneumonia at a high dose (2 g/1 g/8 h). In the era of MDR and with critical patients underrepresented in pivotal studies, off-label use of antimicrobials offers good clinical responses (1). Ceftolozane pharmacokinetics (C-PK) have been assessed under renal support with continuous venovenous hemodiafiltration (CVVHDF) (2–4), but the effect of molecular-adsorbent-recirculating-system (MARS; Baxter, Deerfield, IL) since liver support on C-PK has yet to be documented. This circuit removes both protein-bound and water-soluble molecules through a large-pore hemodialyzer, and little is known about the impact of potentially enhanced antibiotic clearance under this device on patient outcome.

A 37-year-old woman diagnosed with acute lymphoblastic leukemia was admitted to the medical intensive care unit with septic shock secondary to P. aeruginosa permanent catheter-related bacteremia. After initial improvement, the patient experienced hemodynamic and renal deterioration. Abdominal computed tomographic imaging revealed typhlitis. Empiric antimicrobials were changed to high-dose 3-h-infusion C/T, metronidazole, linezolid, and anidulafungin. CVVHDF was initiated using an oXiris filter (Baxter, Meyzieu, France), a polyethylenimine and unfractionated heparin-coated AN69 membrane with a 1.5-m2 surface area, and blood flow, replacement, and dialysate fluid rates of 180 ml/min, 1600 ml/h, and 500 ml/h, respectively. Shortly afterward, the liver function declined, with refractory encephalopathy and hyperbilirubinemia. An 8-h MARS session was added, and high-dose 3 h-infusion C/T was maintained without any related adverse effects. Anidulafungin-resistant Candida tropicalis fungemia was documented. Unfortunately, the patient remained refractory to treatment and died after life support withdrawal.

Serum ceftolozane concentrations (SCC) were measured by high-performance liquid chromatography after drug infusion and immediately before the next scheduled dose under three scenarios (Fig. 1). The following pharmacokinetic (PK) parameters were determined by noncompartmental analysis during MARS and CVVHDF: clearance, 3.39 liters/h; volume of distribution, 24.0 liters; elimination half-life, 5.3 h; AUC0–8, 589 mg/h/liter (calculated by log-linear trapezoidal rule); and extraction ratio, 15.3 ± 6.9%. SCC are shown in Table 1 . Our findings are similar to results obtained in a previous study evaluating elimination under MARS of extended infusion of piperacillin-tazobactam, with a comparable 20 to 30% protein binding profile as C/T: similar concentrations under a 7-h session, with >50% existing drug in the access line present in the return one, and surpassing the desired MIC for Gram-negative infection treatment (5). Concerning renal support, the ceftolozane Cmin was slightly higher than that reported by Oliver et al. (51 versus 31 mg/liter) (4), both with similar filtration flow (2 liters/h) and extended infusion, but with higher C/T dosage (2 g/1 g/8 h). However, SCC were comparable to previous reports with the same high dose and lower time 1 h-infusion (Cmin = 50 to 56 mg/liter) despite a higher flow rate of 3 liters/h (2, 3). The SCC far exceeded the recommended concentration of four times the P. aeruginosa susceptibility breakpoint (4 μg/ml) throughout the dosing interval in all three scenarios (Fig. 1), suggesting that high-dose extended infusion of C/T is unnecessary for susceptible strains. The limitations of the present study include omitted tazobactam concentration measurement and different flow rates used with extracorporeal devices.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Simulation of ceftolozane plasma concentrations over time under three scenarios: (i) CVVHDF, (ii) 8-h MARS+CVVHDF session, and (iii) after withdrawal of both. Circles represent experimental plasma concentrations. MIC, the ceftolozane minimum inhibitory concentration for P. aeruginosa according to the European Committee on Antimicrobial Susceptibility Testing breakpoint.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Serum ceftolozane concentrations in pre- and postcombination systems (i.e., MARS and CVVHDF)a

In conclusion, we confirm already-known results on C-PK under renal replacement therapy, but to our knowledge this is the first published report on C-PK in a critically ill patient during MARS therapy, with high-dosage 3-h-infusion C/T maintaining safe SCC even for MDR P. aeruginosa. Additional PK studies are required to validate these findings.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Xipell M,
    2. Paredes S,
    3. Fresco L,
    4. Bodro M,
    5. Marco F,
    6. Martínez JA,
    7. Soriano A
    . 2018. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist 13:165–170. doi:10.1016/j.jgar.2018.01.010.
    OpenUrlCrossRef
  2. 2.↵
    1. Kuti JL,
    2. Ghazi IM,
    3. Quintiliani R, Jr,
    4. Shore E,
    5. Nicolau DP
    . 2016. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 48:342–343. doi:10.1016/j.ijantimicag.2016.06.005.
    OpenUrlCrossRef
  3. 3.↵
    1. Aguilar G,
    2. Ferriols R,
    3. Martínez-Castro S,
    4. Ezquer C,
    5. Pastor E,
    6. Carbonell JA,
    7. Alós M,
    8. Navarro D
    . 2019. Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration. Crit Care 23:145. doi:10.1186/s13054-019-2434-5.
    OpenUrlCrossRef
  4. 4.↵
    1. Oliver WD,
    2. Heil EL,
    3. Gonzales JP,
    4. Mehrotra S,
    5. Robinett K,
    6. Saleeb P,
    7. Nicolau DP
    . 2015. Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother 60:1899–1901. doi:10.1128/AAC.02608-15.
    OpenUrlCrossRef
  5. 5.↵
    1. Personett HA,
    2. Larson SL,
    3. Frazee EN,
    4. Nyberg SL,
    5. El-Zoghby ZM
    . 2015. Extracorporeal elimination of piperacillin/tazobactam during molecular adsorbent recirculating system therapy. Pharmacotherapy 35:e136–e139. doi:10.1002/phar.1618.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
Nieves Carbonell, Gerardo Aguilar, Rafael Ferriols, Rotzel Huerta, José Ferreres, Marisa Calabuig, Mar Juan, Carlos Ezquer, Javier Colomina, M. Luisa Blasco
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01782-19; DOI: 10.1128/AAC.01782-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
Nieves Carbonell, Gerardo Aguilar, Rafael Ferriols, Rotzel Huerta, José Ferreres, Marisa Calabuig, Mar Juan, Carlos Ezquer, Javier Colomina, M. Luisa Blasco
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01782-19; DOI: 10.1128/AAC.01782-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Pseudomonas aeruginosa
ceftolozane-tazobactam
continuous venovenous hemodiafiltration
medical intensive care unit
molecular adsorbent recirculating system
off-label
pharmacokinetics

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596